US Edition
Published • loading... • Updated
Lupin Launches Topiramate Extended-Release Capsules in the US
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Lupin launches Topiramate Extended-Release Capsules in the US
Lupin today announced the launch of Topiramate Extended-Release Capsules in strengths of 25 mg, 50 mg, 100 mg, and 200 mg in the United States, following approval of its Abbreviated New Drug Application by the U.S. Food and Drug Administration. Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug Trokendi XR Extended-Release Capsules of Supernus Pharmaceuticals, Inc. The product is indicated as initial monotherapy …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
